MARKET

IPHA

IPHA

Innate Pharma Sa
NASDAQ
1.772
-0.008
-0.45%
Closed 15:57 07/27 EDT
OPEN
1.840
PREV CLOSE
1.780
HIGH
1.840
LOW
1.772
VOLUME
2.52K
TURNOVER
0
52 WEEK HIGH
2.630
52 WEEK LOW
1.170
MARKET CAP
166.04M
P/E (TTM)
-2.7507
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IPHA last week (0720-0724)?
Weekly Report · 1d ago
Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference
Barchart · 5d ago
Innate Pharma completes enrollment in dose escalation of IPH4502 study
TipRanks · 07/21 09:30
Innate Pharma Completes Phase 1 Enrollment Of Nectin-4 Exatecan ADC IPH4502, Guiding Dose Optimization With Year-End Preliminary Data Readout
Benzinga · 07/21 05:28
Innate Pharma completes Phase 1 dose-escalation enrollment for Nectin-4 ADC IPH4502 study
PUBT · 07/21 05:06
Innate Pharma notifies availability of press release on IPH4502 Phase 1 dose-escalation enrollment completion
PUBT · 07/21 05:00
Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)
Barchart · 07/21 00:00
Weekly Report: what happened at IPHA last week (0713-0717)?
Weekly Report · 07/20 09:09
More
About IPHA
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.

Webull offers Innate Pharma SA (ADR) stock information, including NASDAQ: IPHA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IPHA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IPHA stock methods without spending real money on the virtual paper trading platform.